InVivo CEO plans big: 5 key notes on capturing the spinal injury market

Spinal Tech

The Boston Business Journal interviewed InVivo Therapeutics' CEO Mark Perrin about how his company plans to take the spine injury market by storm.

Here are five things to know about the company:

 

1. InVivo's shares have increased 177 percent this year so far after adding patients to a clinical trial using the Neuro-Spinal Scaffold for spinal cord injury.

 

2. The shares reached $14.61 this year, and positive news from current and future patients in the trial could spark additional growth.

 

3. The current clinical trial includes both young and active patients as well as an older patient who could benefit from the spinal cord injury treatment. The older patient went from having complete paralysis to incomplete paralysis after a month.

 

4. There are not any other players in this particular market for spinal cord injury treatment, making the field open if the implant proves effective.

 

5. The company's treatments are gaining attention outside the clinical realm. The first two patients treated are young and active on social media, providing updates on their condition. They are also attracting attention for becoming romantically involved after their injuries.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers